Tag: lung cancer
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.
2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.
2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. In this study comparing three prominent lung cancer screening strategies, all were found to be cost-effective, yielding incremental cost-effectiveness ratios of under $100,000/quality adjusted life-year gained, the commonly referenced U.S. willingness-to-pay threshold.
2. As the maximum age for screening eligibility increased, greater reductions in cancer mortality were realized but...
1. In this modelling study, life-gained-based selection of smokers for lung cancer screening resulted in a nearly threefold greater gain in life expectancy per lung cancer death averted compared to risk-based selection but prevented fewer lung cancer deaths overall.
2. While risk-based selection for screening had the potential to prevent...
The following study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Radiology: Summaries of Clinically Relevant & Recent Landmark Studies, 1e (The Classics Series).
1. The American College of Radiology (ACR) developed the Lung Imaging Reporting and Data System (Lung-RADS) to standardize reporting and management of...
1. Prediction tool may help physicians better personalize screening discussions with patients.
2. Benefits of the prediction tool, low-dose computer tomography (LDCT), was shown to be highest in patients with higher-risk for lung cancer and longer life expectancy.
Evidence Rating Level: 2 (Good)
Study Rundown: Lung cancer is one of the most...
1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency.
2. However, the increases in efficiency were attenuated when measured by life-years, quality-adjusted life-years (QALYs), and cost-effectiveness.
Evidence Rating Level: 2 (Good)
Study Rundown: Current guidelines for lung cancer screening...
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC).
2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients...
First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
Platinum-based combination chemotherapy has long been used in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). However, chemotherapy only provides moderate benefit, with median progression-free survival and overall survival limited to 4-6 months and 10-13 months, respectively....
1. In a retrospective review of over 17 000 patients in the National Lung Screening Trial (NLST), there was a high prevalence of potentially significant extra-pulmonary findings.
2. The incidence of extrapulmonary malignancy detected in NLST was low.
Evidence Rating Level: 3 (Average)
Study Rundown: The NLST was a large randomized controlled...